Status:
TERMINATED
Ghrelintrial With Patients With Stroke
Lead Sponsor:
Kantonsspital Winterthur KSW
Conditions:
DEMMMI, Nine-Hole-PEG-Test, mRS
Stroke, Acute
Eligibility:
All Genders
18-90 years
Brief Summary
Patients are assigned to KSW's Stroke Unit as part of the emergency treatment. There the patients are included in the study and treated according to the concept on the Stroke Unit within the complex t...
Detailed Description
Ghreline is a peptide hormone which is produced particularly by cells of the stomach mucous membrane and has an appetizing effect. Nevertheless, the last studies in the person as well as in the animal...
Eligibility Criteria
Inclusion
- Male and female patients
- acute ischemic insult
- functionally relevant motor hemisymptomatic
- up to 7 days after the event
- age from 18 to 90 years
- written approval of the participant after occurred clarification
Exclusion
- Dysphagia
- Nutritional-Risk-Screening (NRS) = 3
- Neuro-degenerative illnesses
- Patients with strokes in the past
- Patients with clinically relevant Polyneuropathy
- Patients with walking disturbance on account of mikroangiopathic changes
- Patients with psychiatric preillnesses (depression, schizophrenia) and anti- depressive and neuroleptic medication
- Patients with rheumatic illnesses with effects on the walking and Hand function
- Patients with innate and/or acquired substance defects of the brain and/or spinal cord (functionally relevant brain tumour, St. n. Encephalitis, brain damage as an infant)
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2019
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03264742
Start Date
April 1 2017
End Date
February 28 2019
Last Update
March 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Winterthur
Winterthur, Switzerland, 8400